| Predicate |
Object |
| assignee |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_bd4cc2aacf8b71b6892dd007aa277497 |
| classificationCPCAdditional |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/G01N2800-7042
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C12Q2600-158 |
| classificationCPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P35-00
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K45-06
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K39-395
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K39-3955
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07K16-38
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C12Q1-6886
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K31-704
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K31-136
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K33-24
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/G01N33-68 |
| classificationIPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K39-395
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P35-00 |
| filingDate |
2019-03-05-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| inventor |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_46e71c062aacf1a1e25dcba35f88190a
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_b88d66f408a273e2495384c5bc3224f6 |
| publicationDate |
2020-04-16-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationNumber |
WO-2020073593-A1 |
| titleOfInvention |
Use of serine protease inhibitor kazal type 1 in the preparation of agent for diagnosing or regulating cell senescence and tumors |
| abstract |
Disclosed is a use of serine protease inhibitor Kazal type 1 (SPINK1) in the preparation of an agent for diagnosing or regulating cell senescence and tumors. SPINK1 plays an important biological role in SASP phenotype and a tumor microenvironment, and is closely correlated with prognosis after chemotherapy. Thus, SPINK1 can serve as a target for research on SASP phenotype regulation as well as anti-tumor research on the basis of tumor microenvironment, as a marker for prognostic assessment and pathological grading of tumor after chemotherapy, and as a target for developing a tumor-inhibiting drug. |
| isCitedBy |
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/CN-113774025-A
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/CN-113774025-B |
| priorityDate |
2018-10-11-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| type |
http://data.epo.org/linked-data/def/patent/Publication |